New model could predict lymphoma progression two years early
NCT ID NCT03436602
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aims to create a more accurate tool to predict whether follicular lymphoma patients will remain free of disease progression two years after their first treatment. Researchers will combine clinical information with molecular data from 370 patients to build and test this model. The goal is to better identify which patients are likely to do well and which may need closer monitoring or different treatment approaches.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Arcispedale Santa Maria Nuova, AUSL IRCSS, Hematology Department
Reggio Emilia, RE, 42123, Italy
-
Azienda Ospedaliera Universitaria Maggiore della Carità
Novara, 28100, Italy
-
Institute of Oncology Research
Bellinzona, Canton Ticino, 6500, Switzerland
-
Institute of Pathology
Locarno, Canton Ticino, Switzerland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Triple-Drug combo wipe out Slow-Growing lymphomas?
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Can a targeted pill boost Chemotherapy's punch against lymphoma?
- Can donor immune cells be engineered to fight blood cancer?
- Can a simple blood test spot lymphoma earlier?
- Can a targeted drug beat radiation for early-stage lymphoma?